Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
NCT03215264Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydroxychloroquine and entinostat in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Abramson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 18 months. Started Oct 2017; status: completed.
02
Drugs
hydroxychloroquineentinostat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03215264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215264.